Fortress Biotech, Inc. (NASDAQ:FBIOP) Short Interest Down 78.4% in June

Fortress Biotech, Inc. (NASDAQ:FBIOP) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 1,100 shares, a drop of 78.4% from the May 31st total of 5,100 shares. Based on an average daily trading volume, of 10,300 shares, the short-interest ratio is presently 0.1 days.

Fortress Biotech Stock Performance

Shares of Fortress Biotech stock traded down $0.13 during midday trading on Thursday, hitting $15.80. The company’s stock had a trading volume of 2,604 shares, compared to its average volume of 11,322. The stock has a 50-day simple moving average of $15.85 and a 200-day simple moving average of $14.99. Fortress Biotech has a 1-year low of $6.40 and a 1-year high of $18.73.

Fortress Biotech Dividend Announcement

The firm also recently announced a monthly dividend, which will be paid on Sunday, June 30th. Stockholders of record on Saturday, June 15th will be given a $0.1953 dividend. The ex-dividend date is Friday, June 14th. This represents a $2.34 annualized dividend and a dividend yield of 14.83%.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.